DE3432882A1 - Enhanced blood flow compositions with vitamin E - Google Patents

Enhanced blood flow compositions with vitamin E

Info

Publication number
DE3432882A1
DE3432882A1 DE19843432882 DE3432882A DE3432882A1 DE 3432882 A1 DE3432882 A1 DE 3432882A1 DE 19843432882 DE19843432882 DE 19843432882 DE 3432882 A DE3432882 A DE 3432882A DE 3432882 A1 DE3432882 A1 DE 3432882A1
Authority
DE
Germany
Prior art keywords
vitamin
lecithin
blood flow
dimethylaminoethanol
enhanced blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19843432882
Other languages
German (de)
Inventor
Roshdy Dipl.-Chem. Dr. 5000 Köln Ismail
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE19843432882 priority Critical patent/DE3432882A1/en
Priority to US06/700,462 priority patent/US4612194A/en
Priority to EP85101554A priority patent/EP0152106B1/en
Priority to AT85101554T priority patent/ATE67665T1/en
Priority to CA000474194A priority patent/CA1261750A/en
Priority to DE8585101554T priority patent/DE3584174D1/en
Publication of DE3432882A1 publication Critical patent/DE3432882A1/en
Priority to US06/898,499 priority patent/US4983626A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Enhanced blood flow compositions in capsule form by the use of dimethylethanolamine and vitamin E, especially vitamin A and E and lecithin, by the use of lecithin and the absorption of the fat-soluble vitamins, especially vitamin A, which is present in the content in small amount, is greatly increased and thus the effect thereof is increased.

Description

Verstärkte Durchblutungsmittel mit Vitamin EReinforced blood circulation agents with vitamin E.

Es wurde in der Anmeldung P 3429019-2 gefunden, daß die Kombination von Vitamin E bzw. A + E mit Dimethylaminoäthanol sowie seinen Derivaten bzw. Salze wesentlich bessere Wirkung zeigen. Die Durchblutung des Gehirns, die Stimmulation des Zentralnervensystems und das Konzentrationsvermögen wurde wesentlich gesteigert und zeigt dadurch eine bessere Wirkung als Dimethylaminoäthanol alleine. Außerdem wird die Durchblutunz der Pherisherie des Cerebrum bzw. der Augen und des Mittelohrs gestetgeDtvr Dlese Kombination ist zum erstenmal in einer Kapsel durchgeführt worden.It was found in the application P 3429019-2 that the combination of vitamin E or A + E with dimethylaminoethanol and its derivatives or salts show a significantly better effect. The blood flow to the brain, the stimulation of the central nervous system and the ability to concentrate have been significantly increased and thus show a better effect than dimethylaminoethanol alone. In addition, the blood circulation of the pherishery of the cerebrum or the eyes and the middle ear stetgeDtvr The combination was carried out for the first time in a capsule.

Diese Kombination ist ideal für ältere Menschen oder für Jugendliche, die unter Konzentrationsmangel leiden. Es muß dabei jedoch das Vitamin E in ausreichend hoher Dosierung verwendet werden (zwischen 150 mg und 600 mg, insbesondere zwischen 200 und 500 mg).This combination is ideal for the elderly or for young people, who suffer from lack of concentration. However, the vitamin E must be sufficient high doses can be used (between 150 mg and 600 mg, especially between 200 and 500 mg).

Typische Beispiele sind mit 300 - 450 mg.Typical examples are with 300-450 mg.

Man kann Dimethylaminoäthanol oder seine Derivate. insbesonders tartrat, Orotat und Acetaminobenzoatazu verwenden.One can use dimethylaminoethanol or its derivatives. especially tartrate, orotate and acetaminobenzoata to use.

Die Dosierung pro Einheit bzw. pro Kapsel beträgt an Dimethylaminoäthanol zwischen 5 - 100 mg, insbesonders aber zwischen 10 - 50 mg.The dosage per unit or per capsule is dimethylaminoethanol between 5 - 100 mg, but especially between 10 - 50 mg.

Vitamin A kann besonders als Palmitat oder weiteres Vitamin A-Derivat wie Acetat verwendet werden.Vitamin A can especially be used as a palmitate or another vitamin A derivative such as acetate can be used.

In allen seinen Alphaformen sowie Ester kann Vitamin A verwendet werden.Vitamin A can be used in all of its alpha forms as well as esters.

Man kann auch weitere Vitamine, insbesonders eine oder mehrere Vitamine der B-Reihe oder weitere- Zusatzstoffe (Nicotinsäureamid, Magnesium-Calcium Salze) zusetzen, um die Leistung zu steigern..You can also add other vitamins, especially one or more vitamins the B series or other additives (nicotinic acid amide, magnesium-calcium salts) add to increase performance ..

Es wurde überraschenderweise gefunden, daß die Kombination obiger Produkte mit Lecithin stark die Resorbtion der fettlöslichen Vitamine begünstigt und demzufolge deren Wirkung erhöht. Außerdem ist Dimethyläthanolamin ein biologisches Abbauprodukt des Lecithins, so daß die Wirkung des Gesamtpräparates durch Lecithin gesteigert wird. Es wird Sojalecithin bevorzugt verwendet. Es wird dadurch hier folgende Formel beansprucht: CH2 - OP - Hydrophile Gruppe R = Fettrest Hydrophile Gruppe sind hauptsächlich Derivate des Athanolamins, worin der Stickstoffatom in Form von Tertiäre Gruppe als Lecithin oder die Hydrophile Gruppe Serin oder Inosit sein kann. Lecithin kann zwischen 1 - 50 % in Gewicht pro Kapsel, insbesonders als Emulgator zwischen 1 und 13 verwendet werden.It has surprisingly been found that the combination of the above products with lecithin strongly favors the absorption of the fat-soluble vitamins and consequently increases their effectiveness. In addition, dimethylethanolamine is a biological degradation product of lecithin, so that the effect of the entire preparation is increased by lecithin. Soy lecithin is preferred. As a result, the following formula is claimed here: CH2 - OP - hydrophilic group R = fat residue Hydrophilic group are mainly derivatives of ethanolamine, in which the nitrogen atom in the form of tertiary group as lecithin or the hydrophilic group can be serine or inositol. Lecithin can be used between 1 - 50% by weight per capsule, especially as an emulsifier between 1 and 13.

Beispiel I 20 mg Dimethylaminoäthanol 200 mg Dl-alpha-Tocopherolacetat 12000 I.E. Vitamin A Palmitat (6,67 mg) 50 mg Sojaöl 250 mg Sojalecithin Beispiel 2 35 mg Dimethylaminoäthanolorotat 400 mg Dl-alpha-Tocopherolacetat 15000 I.E. Vitamin A Palmitat (8,33 mg) 20 mg Sojalecithin Beispiel 3 genau gemäß Beispiel I jedoch mit 3 mg Tween 80 angesetzt.Example I 20 mg of dimethylaminoethanol, 200 mg of Dl-alpha-tocopherol acetate 12000 I.U. Vitamin A palmitate (6.67 mg) 50 mg soy oil 250 mg soy lecithin Example 2 35 mg dimethylaminoethanol orotate 400 mg Dl-alpha-tocopherol acetate 15,000 I.U. vitamin A palmitate (8.33 mg) 20 mg soy lecithin Example 3 exactly as in Example I, however made up with 3 mg Tween 80.

Beispiel 4 35 mg Dimethylaminoäthanol orotat 500 mg D-alpha-Tocopherol-Konzentrat 22000 I.E. Vitamin-A-Palmitat (12,22 mg) 28 mg Sojalecithin Beispiel 5 gemäß Beispiel 4 jedoch mit 4 mg + 250 mg Sojalecithin Tween 20.Example 4 35 mg of dimethylaminoethanol orotate 500 mg of D-alpha-tocopherol concentrate 22,000 I.U. Vitamin A palmitate (12.22 mg) 28 mg soy lecithin Example 5 according to Example 4 but with 4 mg + 250 mg soy lecithin Tween 20.

Beispiel 6 30 mg Dimethylaminoäthanolorotat 400 mg Dl-alpha-Tocopherolacetat 200 mg Lecithin 4 mg Tween 80 Beispiel 7 35 mg Dimethylaminoäthanolorotat 350 mg D-alpha-Tocopherolacetat 15000 I.E. Vitamin-A-Palmitat je 5 mg von Vitamin B1, B2, B6 5 g Vitamin B12 15 mg Nicotinsäureamid 280 mg Lecithin Beispiel 8 gemäß Beispiel 7 jedoch mit 3 mg Tween 80.Example 6 30 mg of dimethylaminoethanol orotate, 400 mg of Dl-alpha-tocopherol acetate 200 mg lecithin 4 mg Tween 80 Example 7 35 mg dimethylaminoethanol orotate 350 mg D-alpha tocopherol acetate 15,000 I.U. Vitamin A palmitate 5 mg of each vitamin B1, B2, B6 5 g vitamin B12 15 mg nicotinic acid amide 280 mg lecithin Example 8 according to the example 7 but with 3 mg Tween 80.

In allen Beispielen wurde Sojaöl zwischen 50 - 150 mg pro Kapsel zugesetzt.In all examples, soybean oil was added between 50-150 mg per capsule.

Beispiel 9 25 mg Dimethylaminoorotat 350 mg Dl-a-Tocopherolacetat 17000 i.E. (9,44 mg) Vitamin-A-Palmitat 70 mg Sojaöl 200 mg Sojalecithin 6 mg Cetiol (dlsäureoleyester)Example 9 25 mg of dimethylaminoorotate, 350 mg of Dl-α-tocopherol acetate 17000 IU (9.44 mg) vitamin A palmitate 70 mg soy oil 200 mg soy lecithin 6 mg cetiol (diacid oleyester)

Claims (5)

Patentansprüehe: 1. Mittel zur Durchblutung des Gehirns, Stimulation des Zentralnervensystems, Durchblutung der Peripherie- und des Cerebrum, Augen und Mittelohr sind dadurch gekennzeichnet, daß man Dimethylaminoäthanol oder seine Derivate mit Vitamin E bzw. Vitamin A + E in einer Dosierung für Vitamin E zwischen 150 - 600 mg, insbesondere 200 - 500 mg und Lecithin pro Einheit verwendet.Claims: 1. Means for blood circulation in the brain, stimulation of the central nervous system, blood flow to the periphery and cerebrum, eyes and Middle ear are characterized by the fact that one dimethylaminoethanol or its derivatives with vitamin E or vitamin A + E in a dose for vitamin E between 150 - 600 mg, especially 200-500 mg and lecithin are used per unit. 2. Mittel nach Anspruch 1 dadurch gekennzeichnet, daß man Lecithin in einem Gewibhtsprozent zwischen o,4 - 50 %, insbesondere als Emulgator zwischen o,4 - 13 % verwendet.2. Means according to claim 1, characterized in that one lecithin in a percent by weight between 0.4 - 50%, especially as an emulsifier between o, 4-13% used. 3. Das Mittel nach Anspruch 1 - 2 ist dadurch gekennzeichnet, daß man Vitamin E in seiner.Alphaform bzw. Ester verwendet.3. The agent according to claim 1-2 is characterized in that one uses vitamin E in its alpha form or ester. 4. Nach Anspruch 1 - 3 wird es dadurch gekennzeichnet, daß man Dimethylaminoäthanol oder seine Derivate, insbesondere Dimethylaminoorot oder Dimethylaminotartarat dazu verwendet.4. According to claim 1-3, it is characterized in that one dimethylaminoethanol or its derivatives, especially dimethylamino or red or dimethylaminotartarate used. 5. In Anspruch 1 - 4 ist das Mittel dadurch gekennzeichnet, daß man sie zur Durchblutung des Mittelohrs bzw. gegen Ohrensausen iTerweiidet. 5. In claim 1-4, the agent is characterized in that it is used for blood flow to the middle ear or against ringing in the ears iTerweiidet.
DE19843432882 1984-02-15 1984-09-07 Enhanced blood flow compositions with vitamin E Withdrawn DE3432882A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DE19843432882 DE3432882A1 (en) 1984-09-07 1984-09-07 Enhanced blood flow compositions with vitamin E
US06/700,462 US4612194A (en) 1984-02-15 1985-02-11 Anti-rheumatic agents and their use
EP85101554A EP0152106B1 (en) 1984-02-15 1985-02-13 Antirheumatic compositions
AT85101554T ATE67665T1 (en) 1984-02-15 1985-02-13 ANTI-RHEUMED.
CA000474194A CA1261750A (en) 1984-02-15 1985-02-13 Anti-rheumatic agents and their use
DE8585101554T DE3584174D1 (en) 1984-02-15 1985-02-13 RHEUMA means.
US06/898,499 US4983626A (en) 1984-02-15 1986-08-21 Anti-rheumatic agents and their use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19843432882 DE3432882A1 (en) 1984-09-07 1984-09-07 Enhanced blood flow compositions with vitamin E

Publications (1)

Publication Number Publication Date
DE3432882A1 true DE3432882A1 (en) 1986-03-20

Family

ID=6244853

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19843432882 Withdrawn DE3432882A1 (en) 1984-02-15 1984-09-07 Enhanced blood flow compositions with vitamin E

Country Status (1)

Country Link
DE (1) DE3432882A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4405545A1 (en) * 1994-02-22 1995-08-31 Dietl Hans Oral vitamin compsn. with improved resorption

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4405545A1 (en) * 1994-02-22 1995-08-31 Dietl Hans Oral vitamin compsn. with improved resorption

Similar Documents

Publication Publication Date Title
DE69118859T2 (en) Treatment of sleep disorders using certain antidepressants, e.g. Nefazodon
DE69404675T2 (en) PHARMACEUTICAL COMPOSITION FOR INTRANASAL ADMINISTRATION OF HYDROXOCOBALAMINE
DE1792410B2 (en) Medicinal preparation for intravenous injection
EP0343694A2 (en) Agent for the treatmment and protection of the skin
EP0413171A1 (en) Strong analgesic composition and process for its preparation
DE3875867T2 (en) CALCIUM ADDITIVES.
DE69201660T2 (en) Use of acetyl L-carnitine for the therapeutic treatment of coma.
WO2010057804A1 (en) Fat emulsion for artificially feeding seriously ill intensive care patients
DE60002226T2 (en) COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF CIRCULAR DISORDERS, CONTAINING L-CARNITIN DERIVATIVES AND GINKGO BILOBA EXTRACTS
EP0198172B1 (en) Pharmaceutical preparation
DE69025787T2 (en) Prophylaxis for atopy
DE60206280T2 (en) USE OF EXTRACTS FROM GINKGO BILOBA FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF SARCOPENIA
DE60124516T3 (en) COMBINATION OF THE LEZITHINE WITH ASCORBIC ACID
DE69023939T2 (en) Promotion of osteogenesis through the use of vitamin D derivatives.
DE3644677A1 (en) MEANS FOR IMPROVING THE BLOOD PROPERTY
DE3432882A1 (en) Enhanced blood flow compositions with vitamin E
EP0279867A2 (en) Use of vitamin E and combinations of vitamin E with anti-inflammatory agents and analgesics in the treatment of rheumatic diseases
DE19650778A1 (en) Dopamine receptor antagonists
DE69214979T2 (en) New, dietary preparations based on phosphorus-lipid complexes and their use in sleep disorders
DE69307197T2 (en) Use of 24,25-dihydroxyvitamin-D3 for the manufacture of a medicament for the treatment of rickets
DE3728367C1 (en) Means for immunizing the human body against HIV infections
DE69200794T2 (en) Use of 4,9,11-triene steroids in turkey compositions.
DE3780702T2 (en) USE OF ETODOLAC TO REDUCE BLOOD CONTENT IN URIC ACID.
EP2674159B1 (en) Pharmaceutical compound for liver regeneration
DE3880579T2 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PLASTIC CONSTRUCTION.

Legal Events

Date Code Title Description
8141 Disposal/no request for examination